Further rationale for optimal combined modality treatments.

about

Further rationale for optimal combined modality treatments.

Item

http://www.wikidata.org/entity/Q42350717

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Further rationale for optimal combined modality treatments.

@en

Further rationale for optimal combined modality treatments.

@nl

type

Item

label

Further rationale for optimal combined modality treatments.

@en

Further rationale for optimal combined modality treatments.

@nl

prefLabel

Further rationale for optimal combined modality treatments.

@en

Further rationale for optimal combined modality treatments.

@nl

P1476

Further rationale for optimal combined modality treatments.

@en

P2093

Issam Makhoul

http://www.w3.org/2001/XMLSchema#string

Robert J Griffin

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.

Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.

P304

25831-25832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16117

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ruud P M Dings

P577

2017-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28415727

http://www.w3.org/2001/XMLSchema#string

P932

5432217

http://www.w3.org/2001/XMLSchema#string